Gregor Fürstenberger

Summary

Affiliation: St. Gallen
Country: Switzerland

Publications

  1. ncbi request reprint Insulin-like growth factors and cancer
    Gregor Fürstenberger
    Center for Tumour Detection and Prevention, St Gallen, Switzerland
    Lancet Oncol 3:298-302. 2002
  2. ncbi request reprint Insulin-like growth factors and breast cancer
    G Furstenberger
    Zentrum für Tumordiagnostik und Prävention, St Gallen, Switzerland
    Onkologie 26:290-4. 2003
  3. ncbi request reprint Serum levels of IGF-1 and IGFBP-3 during adjuvant chemotherapy for primary breast cancer
    Gregor Fürstenberger
    Center for Tumor Detection and Prevention, Rorschacherstrasse 150, CH 9006 St Gallen, Switzerland
    Breast 15:64-8. 2006
  4. pmc Real-time PCR of CD146 mRNA in peripheral blood enables the relative quantification of circulating endothelial cells and is an indicator of angiogenesis
    G Furstenberger
    Center for Tumor Detection and Prevention, St Gallen, Switzerland
    Br J Cancer 93:793-8. 2005
  5. pmc Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer
    G Furstenberger
    Center for Tumor Detection and Prevention, Rorschacherstrasse 150, 9006 St Gallen, Switzerland
    Br J Cancer 94:524-31. 2006
  6. ncbi request reprint Complete remission of a metastatic neuroendocrine tumor of the pancreas with capecitabine (Xeloda) monotherapy
    Gregor Fürstenberger
    Tumor Center ZeTuP St Gallen and Chur, Rorschacherstrasse 150, CH 9006 St Gallen, Switzerland
    Cancer Chemother Pharmacol 61:347-8. 2008

Detail Information

Publications6

  1. ncbi request reprint Insulin-like growth factors and cancer
    Gregor Fürstenberger
    Center for Tumour Detection and Prevention, St Gallen, Switzerland
    Lancet Oncol 3:298-302. 2002
    ..IGFBPs, especially IGFBP3, have independent effects on cell growth, for example, IGFBP3 has proapoptotic activities both dependent on and independent of p53...
  2. ncbi request reprint Insulin-like growth factors and breast cancer
    G Furstenberger
    Zentrum für Tumordiagnostik und Prävention, St Gallen, Switzerland
    Onkologie 26:290-4. 2003
    ..Based on interactions with other receptors, including estrogen and epidermal growth factor receptors, combined targeted therapies may improve breast cancer treatment...
  3. ncbi request reprint Serum levels of IGF-1 and IGFBP-3 during adjuvant chemotherapy for primary breast cancer
    Gregor Fürstenberger
    Center for Tumor Detection and Prevention, Rorschacherstrasse 150, CH 9006 St Gallen, Switzerland
    Breast 15:64-8. 2006
    ..IGF-1 levels significantly correlated with IGFBP-3 levels before and during chemotherapy. In conclusion, these chemotherapy regimens do not seem to modulate IGF-1 or IGFBP-3 levels in a favourable or unfavourable way...
  4. pmc Real-time PCR of CD146 mRNA in peripheral blood enables the relative quantification of circulating endothelial cells and is an indicator of angiogenesis
    G Furstenberger
    Center for Tumor Detection and Prevention, St Gallen, Switzerland
    Br J Cancer 93:793-8. 2005
    ..Thus, CD146 real-time PCR may be an easy and reliable approach to quantify CEC in peripheral blood samples and could facilitate the integration of CEC measurements in clinical studies exploring the efficacy of antiangiogenic therapies...
  5. pmc Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer
    G Furstenberger
    Center for Tumor Detection and Prevention, Rorschacherstrasse 150, 9006 St Gallen, Switzerland
    Br J Cancer 94:524-31. 2006
    ..Since this mobilisation of EPC may contribute to tumour neovascularisation an early antiangiogenic therapy in combination with chemotherapy could be beneficial for the success of cancer therapy...
  6. ncbi request reprint Complete remission of a metastatic neuroendocrine tumor of the pancreas with capecitabine (Xeloda) monotherapy
    Gregor Fürstenberger
    Tumor Center ZeTuP St Gallen and Chur, Rorschacherstrasse 150, CH 9006 St Gallen, Switzerland
    Cancer Chemother Pharmacol 61:347-8. 2008